|
RICTOR expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.10733644476113E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.11022302462516E-16 |
| Normal-vs-Stage2 |
3.41090045097303E-10 |
| Normal-vs-Stage3 |
2.88657986402541E-15 |
| Normal-vs-Stage4 |
1.63713487211226E-12 |
| Stage1-vs-Stage2 |
5.036200E-01 |
| Stage1-vs-Stage3 |
2.785400E-01 |
| Stage1-vs-Stage4 |
4.740200E-03 |
| Stage2-vs-Stage3 |
9.092600E-01 |
| Stage2-vs-Stage4 |
1.653160E-01 |
| Stage3-vs-Stage4 |
1.338760E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
3.14270000001393E-06 |
| Normal-vs-Asian |
1.30870003722805E-09 |
| Caucasian-vs-AfricanAmerican |
6.116600E-01 |
| Caucasian-vs-Asian |
3.988200E-01 |
| AfricanAmerican-vs-Asian |
9.213200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
4.12558875950708E-13 |
| Normal-vs-Female |
1.62436730732907E-12 |
| Male-vs-Female |
3.452400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.39469547022486E-11 |
| Normal-vs-Age(41-60Yrs) |
1.22124532708767E-15 |
| Normal-vs-Age(61-80Yrs) |
4.10782519111308E-14 |
| Normal-vs-Age(81-100Yrs) |
3.447500E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
6.957000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.057700E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.410400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.190100E-02 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.612800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.125400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
4.643400E-04 |
| Classical-VS-Follicular |
5.478600E-03 |
| Classical-VS-Other |
4.200200E-01 |
| Classical-VS-Normal |
3.01979996564228E-10 |
| Tall-VS-Follicular |
2.773400E-01 |
| Tall-VS-Other |
4.525000E-01 |
| Tall-VS-Normal |
1.65867319878998E-13 |
| Follicular-VS-Other |
9.006200E-01 |
| Follicular-VS-Normal |
1.64690483472896E-12 |
| Other-VS-Normal |
1.176970E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
<1E-12 |
| Normal-vs-N1 |
2.00149896656399E-11 |
| N0-vs-N1 |
8.583200E-01 |
|
|
